We are live on ! Find out more
BCM

Biomark Capital Management Portfolio holdings

AUM $8.9M
1-Year Est. Return 97.06%
This Fund
S&P 500
This Quarter Est. Return
-2.35%
1 Year Est. Return
+97.06%
3 Year Est. Return
+113.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$77.9M
AUM Growth
+$5.16M
Cap. Flow
+$25M
Cap. Flow %
32.13%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$25M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$68.5M 87.91%
2,205,926
+603,364
+38% +$25M
ADMA icon
2
ADMA Biologics
ADMA
$1.96B
$9.3M 11.94%
1,433,304
– –

Similar funds

OBP
Old Bellows Partners New York $9.01M AUM 83.84% 1-Year Est. Return
HC
Highstar Capital New York $8.59M AUM 3.82% 1-Year Est. Return
SBA
Seven Bridges Advisors New York $9.75M AUM 16.73% 1-Year Est. Return
CIG
Candlewood Investment Group Rye, New York $10.1M AUM 30% 1-Year Est. Return
LRM
Lime Rock Management Westport, Connecticut $7.54M AUM 22.09% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
GA
Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return
CCM
Catalus Capital Management Greenwich, Connecticut $6.09M AUM 3.76% 1-Year Est. Return

Biomark Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Biomark Capital Management held 3 positions worth $77.9M, up 7.1% from $72.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Biomark Capital Management deployed $25M of net new capital in Q2 2016, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 16% a quarter earlier.

  • Biomark Capital Management added most to Juno Therapeutics, Inc. in Q2 2016, an estimated $25M increase.
  • Biomark Capital Management's ten largest holdings make up 100% of its $77.9M portfolio in Q2 2016.
  • Biomark Capital Management opened 0 new positions and closed 0 in Q2 2016.
  • Biomark Capital Management's portfolio value rose 7.1% quarter-over-quarter to $77.9M.

Based on Biomark Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.